Use access key #2 to skip to page content.

IBDvalueinvestin (99.66)

Got The Blues? Cephalon Can Help.

Recs

1

March 17, 2009 – Comments (1) | RELATED TICKERS: CEPH

Got The Blues? Cephalon Can Help.

Many people feeling depressed and feel suicidal with the sharp decline in their assets. Especially those who invested with Madoff as witnessed by two suicides already. But soon CEPH will be able to help you overcome these feelings.

1 Comments – Post Your Own

#1) On March 17, 2009 at 1:55 PM, IBDvalueinvestin (99.66) wrote:

On another path CEPH may have a drug for Cancer Fatigue

Modafinil for the treatment of fatigue in lung cancer: a pilot study. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K.

Addenbrookes Hospital, Cambridge.

Cancer-related fatigue is the most prevalent and distressing symptom experienced by patients with advanced cancer. Central nervous system stimulants have been shown to relieve fatigue in nonmalignant disease. Modafinil is a stimulant with a selective site of action in the brain that is better tolerated than traditional stimulants, such as methylphenidate. The aim of this study was to determine the feasibility of conducting a randomised controlled trial to assess the efficacy and safety of modafinil for the treatment of fatigue in patients with lung cancer. Twenty patients with non-small cell lung cancer were recruited to this open-label study. Modafinil was taken in a fixed dose-titration schedule of 100 mg daily for 7 days followed by 200 mg daily for 7 days. Fifteen patients completed the study. During the study period, there was a rapid and statistically significant reduction in the primary outcome, fatigue (P = 0.001) and the secondary outcomes of daytime sleepiness and depression/anxiety. This improvement in fatigue was also clinically significant. Ten patients chose to continue modafinil after the study and the drug was well-tolerated. It would be both feasible and worthwhile to conduct a definitive randomised controlled trial to determine the role of modafinil in the treatment of cancer-related fatigue.

 

Modafinil (Provigil/Alertec/Modavigil) is a stimulant drug manufactured by Cephalon, and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy, shift work sleep disorder,[1] and excessive daytime sleepiness associated with obstructive sleep apnea.[2]

Modafinil, like other stimulants, increases the release of monoamines but also elevates hypothalamic histamine levels,[3] leading some researchers to consider Modafinil a "wakefulness promoting agent" rather than a classic amphetamine-like stimulant (as evidenced by the difference in c-fos distribution caused by modafinil as compared to amphetamine).[4]

Although modafinil is thought to be effective in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), in 2006 it was specifically rejected by the FDA for use by children for that purpose after Cephalon was rebuffed in its effort to introduce modafinil as a children's drug under the trade name, Sparlon. Cephalon's own label for Provigil now discourages its use by children for any purpose.[5]

Modafinil has been shown to be effective in the treatment of depression,[6] cocaine addiction,[7] Parkinson's Disease,[8] schizophrenia,[9] and disease-related fatigue.[10][11] By law, however, Cephalon is not allowed to market Modafinil for conditions other than those officially approved by the FDA. (in the U.S.)[12]

Modafinil and its chemical precursor Adrafinil were developed by Lafon Laboratories, a French company acquired by Cephalon in 2001.[13] Modafinil is the primary metabolite of adrafinil, and, while their activity is similar, adrafinil requires a higher dose to achieve equipotent effects.

 

 

Report this comment

Featured Broker Partners


Advertisement